Drug Profile
Research programme: urotensin-II receptor antagonists - Johnson and Johnson
Alternative Names: JNJ-39319202; JNJ-39327041Latest Information Update: 16 Dec 2010
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Isoindoles; Piperazines
- Mechanism of Action Urotensin II antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic heart failure
Most Recent Events
- 16 Dec 2010 No development reported for Chronic heart failure in USA (unspecified route)
- 21 Aug 2008 Early research in Chronic heart failure in USA (unspecified route)